Claris started his professional career at Pumilite Block and Supply in 1958. He founded Pumilite Glass and Specialty Company in 1960, which he sold in 1968. He started at Tom Benson Glass Company ...

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product ...

Fintel reports that on May 28, 2025, Wedbush initiated coverage of Aclaris Therapeutics (NasdaqGS:ACRS) with a Outperform ...

WAYNE, Pa., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno ...

In a recent move, Braden Michael Leonard, a significant shareholder of Aclaris Therapeutics, Inc. (NASDAQ: ACRS), has invested over $1.7 million in the company's stock.The transactions, which took ...

The Pennsylvania-based company is reducing its headcount by around 46%, with the changes to begin “immediately” and likely to be completed by the end of June next year. The company entered ...

I’m not deep into the FileMaker development community, but some announcements from Apple subsidiary Claris a few months ago generated quite a bit of interest on TidBITS Talk and should be coming to ...

The biopharmaceutical company signed an exclusive license deal with Biosion for worldwide rights (excluding Greater China) to BSI-045B and BSI-502. BSI-045B, a novel anti-TSLP monoclonal antibody ...